Pulse Biosciences (NASDAQ:PLSE) Trading Down 3.4% - Time to Sell?

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s stock price fell 3.4% during mid-day trading on Thursday . The company traded as low as $15.01 and last traded at $14.80. 99,122 shares were traded during trading, a decline of 46% from the average session volume of 184,770 shares. The stock had previously closed at $15.32.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.

Pulse Biosciences Stock Performance

The company's 50 day moving average is $16.45 and its two-hundred day moving average is $17.52.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insiders Place Their Bets

In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the sale, the chief technology officer directly owned 137,872 shares of the company's stock, valued at $2,261,100.80. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 71.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Tower Research Capital LLC TRC raised its position in shares of Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after buying an additional 838 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. AlphaQuest LLC raised its position in Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after purchasing an additional 1,261 shares during the period. Rhumbline Advisers raised its position in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after purchasing an additional 1,614 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in shares of Pulse Biosciences by 24.6% in the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after purchasing an additional 1,778 shares during the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.